Form 4: Cabaletta Bio, Inc. Executive Arun Das Reports Stock Option Grant

Arun Das, Chief Business Officer of Cabaletta Bio, Inc., reports the acquisition of stock options for 100,000 shares on March 1, 2024.

Summary

• Arun Das, the Chief Business Officer of Cabaletta Bio, Inc., filed a Form 4 on March 4, 2024.
• The report details the grant of stock options to Das on March 1, 2024, for 100,000 shares of Cabaletta Bio's common stock.
• The exercise price of the options is $23.97 per share.
• The options vest over time, with 25% vesting on March 1, 2025, and the remainder vesting in equal quarterly installments over the following three years, contingent upon continued service.

Sentiment

Score: 7

Explanation: The document itself is neutral, simply reporting a standard executive compensation practice. The sentiment is slightly positive as it indicates the company is incentivizing its executives.

Positives

• The granting of stock options to a key executive like the Chief Business Officer can be seen as an incentive to align their interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key talent, aligning their interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Juno Therapeutics (acquired by Celgene) and Kite Pharma (acquired by Gilead) have used similar equity-based compensation strategies.
• The vesting schedule and exercise price are typical for stock option grants in companies of Cabaletta Bio's size and stage of development.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Business Officer to drive company growth.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates